FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2980453909> ?p ?o ?g. }

• W2980453909 endingPage "524" @default.
• W2980453909 startingPage "517" @default.
• W2980453909 abstract "Abstract Background Effective contraception is critical to young women with HIV-associated tuberculosis (TB), as unintended pregnancy is associated with increased perinatal morbidity and mortality. The effects of co-administration of efavirenz and rifampicin on the pharmacokinetics of depot medroxyprogesterone acetate (DMPA) are unknown. We hypothesized that clearance of medroxyprogesterone acetate (MPA) would increase when given with rifampicin and efavirenz, thus increasing risk of ovulation. Methods This pharmacokinetics (PK) study assessed DMPA among HIV/TB coinfected women on an efavirenz-based antiretroviral treatment and rifampicin-based TB treatment. Plasma MPA concentrations and progesterone were measured predose (MPA only) and 2, 4, 6, 8, 10, and 12 weeks after a single DMPA 150 mg intramuscular injection. The primary outcome measure, MPA concentration (&lt;0.1 ng/mL) at week 12, was assessed using exact 95% Clopper-Pearson confidence intervals. MPA PK parameters were calculated using noncompartmental analysis. Results Among 42 PK-evaluable women from 5 African countries, median age was 32 years and median CD4 was 414 cells/mm3. Five women (11.9%; 95% CI, 4.0–25.6%) had MPA &lt;0.1 ng/mL at week 12; of these, one had MPA &lt;0.1 ng/mL at week 10. The median clearance of MPA was 19 681 L/week compared with 12 118 L/week for historical controls. There were no adverse events related to DMPA, and progesterone concentrations were &lt;1 ng/mL for all women for the study duration. Conclusions DMPA, when given with rifampicin and efavirenz, was safe. MPA clearance was higher than in women with HIV not on ART, leading to subtherapeutic concentrations of MPA in 12% of women, suggesting that more frequent dosing might be needed. Clinical Trials Registration NCT02412436." @default.
• W2980453909 created "2019-10-25" @default.
• W2980453909 creator A5005340734 @default.
• W2980453909 creator A5007514947 @default.
• W2980453909 creator A5025069184 @default.
• W2980453909 creator A5025984594 @default.
• W2980453909 creator A5031321827 @default.
• W2980453909 creator A5033183031 @default.
• W2980453909 creator A5038527599 @default.
• W2980453909 creator A5046514885 @default.
• W2980453909 creator A5046741001 @default.
• W2980453909 creator A5052412044 @default.
• W2980453909 creator A5053987417 @default.
• W2980453909 creator A5061325395 @default.
• W2980453909 creator A5075071370 @default.
• W2980453909 creator A5075613250 @default.
• W2980453909 creator A5075758950 @default.
• W2980453909 creator A5077394595 @default.
• W2980453909 creator A5086199837 @default.
• W2980453909 creator A5091320018 @default.
• W2980453909 date "2019-09-05" @default.
• W2980453909 modified "2023-10-17" @default.
• W2980453909 title "Pharmacokinetics and Pharmacodynamics of Depot Medroxyprogesterone Acetate in African Women Receiving Treatment for Human Immunodeficiency Virus and Tuberculosis: Potential Concern for Standard Dosing Frequency" @default.
• W2980453909 cites W159203288 @default.
• W2980453909 cites W1969525670 @default.
• W2980453909 cites W1978207949 @default.
• W2980453909 cites W1993100936 @default.
• W2980453909 cites W2022166029 @default.
• W2980453909 cites W2065379430 @default.
• W2980453909 cites W2088423598 @default.
• W2980453909 cites W2106800262 @default.
• W2980453909 cites W2111348288 @default.
• W2980453909 cites W2116219734 @default.
• W2980453909 cites W2126193337 @default.
• W2980453909 cites W2134424568 @default.
• W2980453909 cites W2145560149 @default.
• W2980453909 cites W2219012755 @default.
• W2980453909 cites W2410577977 @default.
• W2980453909 cites W2556665691 @default.
• W2980453909 cites W2613428583 @default.
• W2980453909 cites W4251644040 @default.
• W2980453909 doi "https://doi.org/10.1093/cid/ciz863" @default.
• W2980453909 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7384316" @default.
• W2980453909 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31504342" @default.
• W2980453909 hasPublicationYear "2019" @default.
• W2980453909 type Work @default.
• W2980453909 sameAs 2980453909 @default.
• W2980453909 citedByCount "6" @default.
• W2980453909 countsByYear W29804539092020 @default.
• W2980453909 countsByYear W29804539092021 @default.
• W2980453909 countsByYear W29804539092023 @default.
• W2980453909 crossrefType "journal-article" @default.
• W2980453909 hasAuthorship W2980453909A5005340734 @default.
• W2980453909 hasAuthorship W2980453909A5007514947 @default.
• W2980453909 hasAuthorship W2980453909A5025069184 @default.
• W2980453909 hasAuthorship W2980453909A5025984594 @default.
• W2980453909 hasAuthorship W2980453909A5031321827 @default.
• W2980453909 hasAuthorship W2980453909A5033183031 @default.
• W2980453909 hasAuthorship W2980453909A5038527599 @default.
• W2980453909 hasAuthorship W2980453909A5046514885 @default.
• W2980453909 hasAuthorship W2980453909A5046741001 @default.
• W2980453909 hasAuthorship W2980453909A5052412044 @default.
• W2980453909 hasAuthorship W2980453909A5053987417 @default.
• W2980453909 hasAuthorship W2980453909A5061325395 @default.
• W2980453909 hasAuthorship W2980453909A5075071370 @default.
• W2980453909 hasAuthorship W2980453909A5075613250 @default.
• W2980453909 hasAuthorship W2980453909A5075758950 @default.
• W2980453909 hasAuthorship W2980453909A5077394595 @default.
• W2980453909 hasAuthorship W2980453909A5086199837 @default.
• W2980453909 hasAuthorship W2980453909A5091320018 @default.
• W2980453909 hasBestOaLocation W29804539091 @default.
• W2980453909 hasConcept C111113717 @default.
• W2980453909 hasConcept C112705442 @default.
• W2980453909 hasConcept C126322002 @default.
• W2980453909 hasConcept C142462285 @default.
• W2980453909 hasConcept C142724271 @default.
• W2980453909 hasConcept C197934379 @default.
• W2980453909 hasConcept C203014093 @default.
• W2980453909 hasConcept C2776306185 @default.
• W2980453909 hasConcept C2777164284 @default.
• W2980453909 hasConcept C2777288759 @default.
• W2980453909 hasConcept C2778607973 @default.
• W2980453909 hasConcept C2781069245 @default.
• W2980453909 hasConcept C2781432083 @default.
• W2980453909 hasConcept C2908647359 @default.
• W2980453909 hasConcept C2993143319 @default.
• W2980453909 hasConcept C3013748606 @default.
• W2980453909 hasConcept C71924100 @default.
• W2980453909 hasConcept C98274493 @default.
• W2980453909 hasConcept C99454951 @default.
• W2980453909 hasConceptScore W2980453909C111113717 @default.
• W2980453909 hasConceptScore W2980453909C112705442 @default.
• W2980453909 hasConceptScore W2980453909C126322002 @default.
• W2980453909 hasConceptScore W2980453909C142462285 @default.
• W2980453909 hasConceptScore W2980453909C142724271 @default.
• W2980453909 hasConceptScore W2980453909C197934379 @default.
• W2980453909 hasConceptScore W2980453909C203014093 @default.
• W2980453909 hasConceptScore W2980453909C2776306185 @default.

• next